

Executive Corridor  
Darlington Memorial Hospital  
Hollyhurst Road  
Darlington  
DL3 6HX  
Switchboard Tel: 01325 38 0100  
Foundation Trust Office: 01325 74 3625  
Corporate Records Office: 01325 74 3700

Request for Information Reference: 03.24.35

FOI Direct line: 01325 743700  
Email: [cdda-tr.cddftfoi@nhs.net](mailto:cdda-tr.cddftfoi@nhs.net)

Email only

3<sup>rd</sup> April 2024

Dear

### Freedom of Information Act 2000 – Request for Information

Thank you for submitting a request for information which we received on 11<sup>th</sup> March 2024 in relation to County Durham and Darlington NHS Foundation Trust (the Trust). Your request has been processed under the provisions of the Freedom of Information Act 2000 and I am now able to provide you with a response.

Your request was in relation to Oncology Supplemental and I am providing the following information in response to your specific questions:

#### Could you please answer the following questions?

1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

<b>CAPOX (Capecitabine with Oxaliplatin)</b>	
<b>FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)</b>	
<b>Lonsurf (Trifluridine - tipiracil)</b>	
<b>Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)</b>	
<b>Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)</b>	
<b>Any other systemic anti-cancer therapy</b>	
<b>Palliative care only</b>	<3

2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

<b>Atezolizumab (Tecentriq)</b>	
<b>Durvalumab (Imfinzi)</b>	
<b>Nivolumab (Opdivo)</b>	
<b>Pembrolizumab (Keytruda)</b>	
<b>Chemotherapy</b>	13
<b>Radiotherapy</b>	0
<b>Chemotherapy AND Radiotherapy</b>	0

3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

<b>Avelumab + Axitinib (Bavencio + Inlyta)</b>	
<b>Cabozantinib (Cometriq)</b>	
<b>Nivolumab (Opdivo)</b>	
<b>Nivolumab + Cabozantinib (Opdivo + Cometriq)</b>	
<b>Nivolumab + Ipilimumab (Opdivo + Yervoy)</b>	
<b>Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)</b>	

The Trust does not provide this service. The therapies are provided by South Tees and recorded on their database and the Trust presently does not have access to the data requested. If you wish to contact South Tees NHS Foundation Trust in accordance with Section 16 of the Act (duty to provide advice and assistance) you can do so via the following address:

South Tees NHS Foundation Trust  
Murray Building  
The James Cook University Hospital  
Marton Road  
Middlesbrough, TS4 3BW  
Email: [stees.foi.admin@nhs.net](mailto:stees.foi.admin@nhs.net)

In line with the Information Commissioner's directive on the disclosure of information under the Freedom of Information Act 2000 your request will form part of our disclosure log on the Trust's website. However please be assured that we anonymise all responses prior to adding them to the disclosure log.

I hope that this response has provided you with the information you had requested. If you have any queries or wish to discuss the information supplied, please do not hesitate to contact me by telephone or in writing. If however, you are dissatisfied with the way in which your request has been handled and would like an internal review, you will need to contact me in writing at the above address or via [cdda-tr.cddffoi@nhs](mailto:cdda-tr.cddffoi@nhs).

If you remain dissatisfied with our response following an internal review you have the right to appeal to The Information Commissioner at Wycliffe House, Water Lane,

Wilmslow, Cheshire, SK9 5AF. More information is available on their website;  
[www.ico.gov.uk](http://www.ico.gov.uk).

Yours sincerely

**Corporate Records and Freedom of Information Facilitator**